AtaiBeckley (ATAI) Accumulated Expenses (2020 - 2026)

AtaiBeckley's (ATAI) quarterly Accumulated Expenses came in at $3.9 million in Q1 2026, down 31.0% quarter-over-quarter from $5.7 million in Q4 2025.

AtaiBeckley (ATAI) Accumulated Expenses (2020 - 2026) Analysis & Trends

AtaiBeckley's Accumulated Expenses history runs 3 years deep, the most recent figure standing at $3.9 million for Q1 2026.

On a quarterly basis, Accumulated Expenses changed N/A year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.7 million, down 42.61% from the prior year.
Accumulated Expenses retreated to $3.9 million in Q1 2026 per ATAI's latest filing, from $5.7 million in the prior quarter.
In the past five years, Accumulated Expenses ranged from a high of $22.1 million in Q3 2022 to a low of $1.7 million in Q1 2024.
A 5-year average of $8.1 million and a median of $4.6 million in 2023 frame the typical range for Accumulated Expenses.
Biggest YoY gain for Accumulated Expenses was 42.61% in 2025; the steepest drop was 42.61% in 2025.
Year by year, Accumulated Expenses stood at $9.8 million in 2024, then sank by 42.61% to $5.7 million in 2025, then tumbled by 31.0% to $3.9 million in 2026.
Per Business Quant, the three latest ATAI Accumulated Expenses figures stand at $3.9 million (Q1 2026), $5.7 million (Q4 2025), and $9.8 million (Q4 2024).

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	AtaiBeckley	2.56 Bn	2.56 Bn	-

Download Data